However, I do not (could not) read the Opinion as the mere knowledge of possible infringement by others amounts to inducement ... as it is opposite the case law.
Teva did not simple had a knowledge but (actively) marketed the infringed use.
My view / opinion about the Teva vs GSK case is the same as it was: it is not (really) relevant for Amarin.
"skinny" label period:
Teva was not liable because of the label but because of specific intent and action to induce infringement was proven.
Warsaw Orthopedic, Inc. v. NuVasive, Inc., 824 F.3d 1344, 1347 (Fed. Cir. 2016)
Rogers v. Missouri Pacific R. Co., 352 U.S. 500, 508, n. 17 (1957)
"Assuming" that generic V has knowledge of the ruling, it defies common sense to expect that generic V will actively promote the sale of its approved icosapent for a use that infringe Amarin's patent. The decision is essentially a roadmap of what not to do. The generics will design any promotional materials, activities or references to their generic drug in a manner to avoid the pitfalls made by Teva. Hikma and Dr. Reddy’s will likely modify (if necessary) any promotional materials, either press releases or product catalogues or communications to the doctors, to specify that any mention of their generic formulation for Vascepa is not indicated for, and not encouraged for treatment of, the cardiovascular indication. That type of simple modification within any promotional materials more likely be enough to avoid infringement of any of Amarin’s R-IT patents.
"full" label period: I do not see any reason to presume that Hikma or Dr. Reddy’s will request or be required by the FDA to do it.
Generic launch - this is all a game of chicken - the Teva case changed the equation.... generics want to make a safe sure fire profit -legal costs are a chicken feed gamble (continuing the theme) but now it’s all about assessing risk and profit for the generics We can all pontificate about where the infringement law was / and now is .... but if you were cock sure(again continuing the theme) about making a killing profit on GV before the Teva case you are currently seriously recalculating now if you are a generic Why risk ? For what reward ? Amarin don’t have to PR to tell the generics what they will do ... they are working it out for themselves .... This is now a watching game ... wait see what happens ... en banc ? Further legal action to get decision changed ?? launch ..??. injunction ???... infringement/damages??
But each day as time passes by the damage shrinks just a little /and potential for Amarin to make profit in USA grows and Europe approval nears ... a slow recovery in SP over time ... hopefully ??? Alm I